COVID-19 therapeutics
Since the emergence of COVID-19 in 2020, an unprecedented range of therapeutic options
has been studied and deployed. Healthcare providers have multiple treatment approaches …
has been studied and deployed. Healthcare providers have multiple treatment approaches …
Emerging anti-spike monoclonal antibodies against SARS-CoV-2
EE Ordaya, RR Razonable - Expert Opinion on Biological Therapy, 2024 - Taylor & Francis
Introduction Anti-spike monoclonal antibodies (mAbs) were previously authorized for the
prevention and treatment of COVID-19 in immunocompromised patients. However, they are …
prevention and treatment of COVID-19 in immunocompromised patients. However, they are …
Carbonized aerogel/ZnO-based dispersive solid phase extraction of daclatasvir and sofosbuvir from biological samples prior to liquid chromatography–tandem mass …
EM Khosrowshahi, RH Sabet, MRA Mogaddam… - … of Pharmaceutical and …, 2024 - Elsevier
Daclatasvir and sofosbuvir are antiviral medications utilized in the treatment of chronic
hepatitis C virus (HCV) infection. Due to their low therapeutic index, careful monitoring is …
hepatitis C virus (HCV) infection. Due to their low therapeutic index, careful monitoring is …
Treatment of chronic COVID‐19 with convalescent/postvaccination plasma in patients with hematologic malignancies
M Janssen, A Leo, C Wolf, M Stenzinger… - … Journal of Cancer, 2024 - Wiley Online Library
Immunocompromised patients are at high risk to fail clearance of SARS‐CoV‐2. Prolonged
COVID‐19 constitutes a health risk and a management problem as cancer treatments often …
COVID‐19 constitutes a health risk and a management problem as cancer treatments often …
Passive immunotherapies for the next influenza pandemic
Influenzavirus is among the most relevant candidates for a next pandemic. We review here
the phylogeny of former influenza pandemics, and discuss candidate lineages. After briefly …
the phylogeny of former influenza pandemics, and discuss candidate lineages. After briefly …
The Role of Convalescent Plasma in COVID-19: A Conclusive Post-Pandemic Review
M Franchini, D Focosi - Life, 2023 - mdpi.com
COVID-19 convalescent plasma (CCP) has represented the frontline response to the COVID-
19 pandemic, largely because of encouraging historical evidences in previous pandemics …
19 pandemic, largely because of encouraging historical evidences in previous pandemics …
Early combination of sotrovimab with nirmatrelvir/ritonavir or remdesivir is associated with low rate of persisting SARS CoV-2 infection in immunocompromised …
I Gentile, G Viceconte, F Cuccurullo, D Pietroluongo… - medRxiv, 2024 - medrxiv.org
Background Immunocompromised patients are at high risk of developing
persisting/prolonged COVID-19. Data concerning early combined use of antivirals and …
persisting/prolonged COVID-19. Data concerning early combined use of antivirals and …